Clinical TrailsMerck, Eisai Advance Dual Oral Therapy with Strong Phase 3 RCC Data at ASCO... Merck, Eisai Advance Dual Oral Therapy with Strong Phase 3 RCC Data at ASCO... Read Post »
Clinical Trails55% Risk Reduction: Ralinepag’s ADVANCE OUTCOMES Results Signal New P... 55% Risk Reduction: Ralinepag’s ADVANCE OUTCOMES Results Signal New P... Read Post »
Clinical TrailsAbbVie’s SKYRIZI Shows Strong Induction Results in Hard-to-Treat Crohn’... AbbVie’s SKYRIZI Shows Strong Induction Results in Hard-to-Treat Crohn’... Read Post »
Clinical TrailsMerck Reports Positive Phase 3 Results Across Ovarian, Bladder, and Renal C... Merck Reports Positive Phase 3 Results Across Ovarian, Bladder, and Renal C... Read Post »
Clinical TrailsSystImmune and BMS Report Dual PFS/OS Wins for Iza-Bren in Advanced TNBC Ph... SystImmune and BMS Report Dual PFS/OS Wins for Iza-Bren in Advanced TNBC Ph... Read Post »
Clinical TrailsOrganon Highlights VTAMA Family Sleep Benefits in ADORING Trials Organon Highlights VTAMA Family Sleep Benefits in ADORING Trials Read Post »
Clinical TrailsLilly’s Olumiant Shows Strong Hair Regrowth in Adolescents with Sever... Lilly’s Olumiant Shows Strong Hair Regrowth in Adolescents with Sever... Read Post »
Clinical TrailsBayer’s PEACE‑3 Phase III Trial Shows Enzalutamide Plus Radium‑223 Im... Bayer’s PEACE‑3 Phase III Trial Shows Enzalutamide Plus Radium‑223 Im... Read Post »
Clinical TrailsGalderma’s Nemluvio Shows Sustained Efficacy and Safety in Prurigo No... Galderma’s Nemluvio Shows Sustained Efficacy and Safety in Prurigo No... Read Post »
Clinical TrailsPalvella Announces Topline Win for QTORIN in Microcystic Lymphatic Malforma... Palvella Announces Topline Win for QTORIN in Microcystic Lymphatic Malforma... Read Post »
Clinical TrailsArgenx Reports Improved Ocular Symptoms in MG with Subcutaneous VYVGART Argenx Reports Improved Ocular Symptoms in MG with Subcutaneous VYVGART Read Post »
Clinical TrailsEli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 ... Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 ... Read Post »
Clinical TrailsViiV’s Lotivibart Hits 94% HIV Control at 12 Months EMBRACE Data ViiV’s Lotivibart Hits 94% HIV Control at 12 Months EMBRACE Data Read Post »
Clinical TrailsAxsome Therapeutics Doses First Patient in CLARITY Phase 3 Trial Axsome Therapeutics Doses First Patient in CLARITY Phase 3 Trial Read Post »
Clinical TrailsPromising Phase 3 Data for Merck’s Doravirine/Islatravir Combo in HIV Promising Phase 3 Data for Merck’s Doravirine/Islatravir Combo in HIV Read Post »
Clinical TrailsBristol Myers Squibb’s Reblozyl Shows Promise in Alpha-Thalassemia: P... Bristol Myers Squibb’s Reblozyl Shows Promise in Alpha-Thalassemia: P... Read Post »
Clinical TrailsNovartis RWE: Pluvicto Delivers 13.5-Month PFS in ARPI-Pre-Treated mCRPC Novartis RWE: Pluvicto Delivers 13.5-Month PFS in ARPI-Pre-Treated mCRPC Read Post »
Clinical TrailsNovo Nordisk-Backed Triple Agonist UBT251 Delivers Strong Phase 2 Results i... Novo Nordisk-Backed Triple Agonist UBT251 Delivers Strong Phase 2 Results i... Read Post »
Clinical TrailsMoonLake’s SLK Shows Strong Results in Phase 2 Trial for Axial Spondy... MoonLake’s SLK Shows Strong Results in Phase 2 Trial for Axial Spondy... Read Post »
Clinical TrailsGossamer Bio’s PROSERA Trial: Narrow Miss on 6MWD, Strong in Advanced... Gossamer Bio’s PROSERA Trial: Narrow Miss on 6MWD, Strong in Advanced... Read Post »
Clinical TrailsCagriSema Delivers 23% Weight Loss in REDEFINE 4: Strong Efficacy, Just Shy... CagriSema Delivers 23% Weight Loss in REDEFINE 4: Strong Efficacy, Just Shy... Read Post »
Clinical Trails Policy & AcquisitionsGilead Snaps Up Arcellx, Eyes Anito-cel Approval in Multiple Myeloma Gilead Snaps Up Arcellx, Eyes Anito-cel Approval in Multiple Myeloma Read Post »
Clinical TrailsFrom Week 44 to 140: New TREMFYA® Evidence Reinforces Long-Term UC Control... From Week 44 to 140: New TREMFYA® Evidence Reinforces Long-Term UC Control... Read Post »
Clinical TrailsTakeda KEPLER Trial: Promising Vedolizumab Results for Pediatric Ulcerative... Takeda KEPLER Trial: Promising Vedolizumab Results for Pediatric Ulcerative... Read Post »
Clinical TrailsViiV Healthcare’s Cabenuva Demonstrates Superior Efficacy in LATITUDE... ViiV Healthcare’s Cabenuva Demonstrates Superior Efficacy in LATITUDE... Read Post »
Clinical TrailsMerck’s ENFLONSIA Shows Promising Safety in Second RSV Season for Hig... Merck’s ENFLONSIA Shows Promising Safety in Second RSV Season for Hig... Read Post »
Clinical TrailsPfizer Advances BRAFTOVI in Colorectal Cancer with New BREAKWATER Results Pfizer Advances BRAFTOVI in Colorectal Cancer with New BREAKWATER Results Read Post »
Clinical TrailsNovartis’ Remibrutinib Shows Promise in Chronic Inducible Urticaria Novartis’ Remibrutinib Shows Promise in Chronic Inducible Urticaria Read Post »
Clinical TrailsViiV Healthcare Highlights Lotivibart and Cabotegravir LA Findings at CROI ... ViiV Healthcare Highlights Lotivibart and Cabotegravir LA Findings at CROI ... Read Post »
Clinical TrailsOcular Therapeutix’s AXPAXLI Achieves Superiority in Wet AMD Phase 3 ... Ocular Therapeutix’s AXPAXLI Achieves Superiority in Wet AMD Phase 3 ... Read Post »
Clinical TrailsSanofi and Teva Report Durable Duvakitug Efficacy at 44 Weeks in UC/CD: REL... Sanofi and Teva Report Durable Duvakitug Efficacy at 44 Weeks in UC/CD: REL... Read Post »
Clinical TrailsUltragenyx Reports Long-Term Success of UX111 Gene Therapy for Sanfilippo S... Ultragenyx Reports Long-Term Success of UX111 Gene Therapy for Sanfilippo S... Read Post »
Clinical TrailsRoche’s Gazyva/Gazyvaro Hits pMN Remission in Phase III MAJESTY Trial Roche’s Gazyva/Gazyvaro Hits pMN Remission in Phase III MAJESTY Trial Read Post »
Clinical TrailsSanofi’s NIRSE-GAL Study Shows Beyfortus Protect Infants Beyond First RSV... Sanofi’s NIRSE-GAL Study Shows Beyfortus Protect Infants Beyond First RSV... Read Post »
Clinical TrailsNovartis Vanrafia® Slows IgAN Kidney Decline Novartis Vanrafia® Slows IgAN Kidney Decline Read Post »
Clinical TrailsAstraZeneca Breztri Boosts FEV1 in Asthma Trials AstraZeneca Breztri Boosts FEV1 in Asthma Trials Read Post »
Clinical TrailsLundbeck Reports Positive Phase IIb Results for Bocunebart in Migraine Lundbeck Reports Positive Phase IIb Results for Bocunebart in Migraine Read Post »
Clinical TrailsINmune Bio Advances XPro1595 to FDA-Aligned AD Trial INmune Bio Advances XPro1595 to FDA-Aligned AD Trial Read Post »
Clinical TrailsBridgeBio’s Infigratinib Achieves Breakthrough Phase 3 Results in Ach... BridgeBio’s Infigratinib Achieves Breakthrough Phase 3 Results in Ach... Read Post »
Clinical TrailsINSIGHTT Trial Approved: Sarepta’s HD Therapy Advances INSIGHTT Trial Approved: Sarepta’s HD Therapy Advances Read Post »
Clinical TrailsFDA Clears ArkBio’s AK3280 IND for Phase 2 IPF Trial FDA Clears ArkBio’s AK3280 IND for Phase 2 IPF Trial Read Post »
Clinical Trails Drugs Safety AlertChugai’s NXT007 Shows Promising Safety During Emicizumab Transition in Ha... Chugai’s NXT007 Shows Promising Safety During Emicizumab Transition in Ha... Read Post »
Clinical TrailsGSK’s Arexvy RSV Vaccine Accepted for Review in China GSK’s Arexvy RSV Vaccine Accepted for Review in China Read Post »
Clinical TrailsAstraZeneca Advances Oral GLP-1 Elecoglipron Toward Phase III AstraZeneca Advances Oral GLP-1 Elecoglipron Toward Phase III Read Post »
Clinical TrailsKyowa Kirin Takes Full Global Control of Rocatinlimab After Amgen Exit Kyowa Kirin Takes Full Global Control of Rocatinlimab After Amgen Exit Read Post »
Clinical TrailsTakeda Announces FDA Acceptance of Oveporexton NDA for NT1 Takeda Announces FDA Acceptance of Oveporexton NDA for NT1 Read Post »
Clinical TrailsRoche’s Fenebrutinib Meets Phase III Endpoint in PPMS Roche’s Fenebrutinib Meets Phase III Endpoint in PPMS Read Post »
Clinical TrailsJohnson & Johnson Reports Results from OMNY-AF Study in A-Fib Johnson & Johnson Reports Results from OMNY-AF Study in A-Fib Read Post »
Clinical TrailsFDA Lifts Prior PCNSL Use Limitation from Gilead’s Yescarta Label FDA Lifts Prior PCNSL Use Limitation from Gilead’s Yescarta Label Read Post »
Clinical TrailsDenali Therapeutics Highlights ETV Platform Progress at WORLDSymposium 2026 Denali Therapeutics Highlights ETV Platform Progress at WORLDSymposium 2026 Read Post »
